Alterations in Locomotor Activity Induced by Radioprotective Doses of 16,16-Dimethyl Prostaglandin E2

  • M. R. Landauer
  • T. L. Walden
  • H. D. Davis
  • J. A. Dominitz


16, 16-Dimethyl prostaglandin E2 (DiPGE2) is an effective radioprotectant when administered before irradiation. A notable side effect of this compound is sedation. In separate experiments, we investigated the dose-response determinations of the time course of locomotor activity and 30-day survival after 10 Gy gamma irradiation (LD100). Adult male CD2F1 mice were injected subcutaneously with vehicle or DiPGE2 in doses ranging from 0.01 to 40 μg/mouse. A dose of 0.01 μg did not result in alterations in locomotor behavior or enhance survival. Doses greater than 1 μg produced ataxia and enhanced radiation survival in a dose-dependent fashion. Full recovery of locomotor activity did not occur until 6 and 30 hr after injection for the 10 μg and 40-μg groups, respectively. Radioprotection was observed when DiPGE2 was administered preirradiation but not postirradiation. Doses of 1 and 10 μg were maximally effective as a radioprotectant if injected 5 min prior to irradiation (80%–90% survival). A dose of 40 μg resulted in 100% survival when injected 5–30 min before irradiation. Therefore, increasing doses of DiPGE2 resulted in enhanced effectiveness as a radioprotectant. However, the doses that were the most radioprotective were also the most debilitating to the animal.


Locomotor Activity Locomotor Behavior Vehicle Control Group Mental Alertness Radioprotective Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hanson, W. R., and Ainsworth, E. J. 16, 16-Dimethyl prostaglandin E2 induces radioprotection in murine intestinal and hematopoietic stem cells. Radiat. Res. 103: 196–203, 1985.PubMedCrossRefGoogle Scholar
  2. 2.
    Waiden, T. L., Jr., Patchen, M., and Snyder, S. L. 16, 16-dimethyl prostaglandin E2 increases survival in mice following irradiation. Radiat. Res. 109: 440–448, 1987.PubMedCrossRefGoogle Scholar
  3. 3.
    Desiraju, T. Effect of intraventricularly administered prostaglandin El on the electrical activity of cerebral cortex and behavior in the unanesthetized monkey. Prostaglandins 3: 859–870, 1973.PubMedCrossRefGoogle Scholar
  4. 4.
    Gilmore, D. P., and Shakh, A. A. The effect of prostaglandin E2 in inducing sedation in the rat. Prostaglandins 2: 143–151, 1972.PubMedCrossRefGoogle Scholar
  5. 5.
    Horton, E. W. Actions of prostaglandins E1, E2, and E3 on the central nervous system. Brit. J. Pharmacol. 22: 189–192, 1964.PubMedGoogle Scholar
  6. 6.
    Weiner, M., and Olson, J. W. Comparative behavioral effects of dibutyryl cyclic AMP and prostaglandin E1 in mice. Prostaglandins 9: 927–943, 1975.PubMedCrossRefGoogle Scholar
  7. 7.
    Chiu, E. K. Y., and Richardson, J. S. Behavioral and neurochemical aspects of prostaglandins in brain function. Gen. Pharmac. 16: 163–175, 1985.CrossRefGoogle Scholar
  8. 8.
    Potts, W. J., East, P. F., and Mueller, R. A. Behavioral effects. In: “The Prostaglandins,” Vol. 2. P. W. Ramwell, ed. Plenum Press, New York, 1974, pp. 157–173.CrossRefGoogle Scholar
  9. 9.
    Snyder, S. L., Waiden, T. L., Jr., MacVittie, T. J., Patchen, M. L., and Fuchs, P. Radioprotective properties of detoxified lipid A from Salmonella minnesota R595. Radiat. Res. 107: 107–114, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Fleiss, J. L. “Statistical Methods for Rates and Proportions.” John Wiley, New York, 1981, pp. 138–143.Google Scholar
  11. 11.
    Landauer, M. R., Davis, H. D., Dominitz, J. D., and Weiss, J. F. Dose and time relationships of the radioprotector WR-2721 on locomotor activity in mice. Pharmacol. Biochem. Behav. 27: 573–576, 1987.PubMedCrossRefGoogle Scholar
  12. 12.
    Landauer, M. R., Davis, H. D., Dominitz, J. D., and Weiss, J. F. Comparative behavioral toxicity of four sulfhydryl radioprotective compounds in mice. WR-2721, cysteamine, diethyldithiocarbamate, and N-acetylcysteamine. Parmac. Ther., in press.Google Scholar
  13. 13.
    Landauer, M. R., Davis, H. D., Dominitz, J. D., and Weiss, J. F. Long-term effects of radioprotector WR-2721 on locomotor activity and body weight of mice following exposure to ionizing radiation. Toxicology, in press.Google Scholar
  14. 14.
    Bito, L. Z., Davson, H., and Hollingsworth, J. R. Facilitated transport of prostaglandins across the blood-cerebrospinal fluid and blood-brain barriers. J. Physiol. 253: 273–285, 1976.Google Scholar
  15. 15.
    Bergstrom, S., Farnebo, L. O., and Fuxe, K. Effect of prostaglandin E2 on central and peripheral catecholamine neurons. Eur. J. Pharmacol. 21: 362–368, 1973.PubMedCrossRefGoogle Scholar
  16. 16.
    Hayaishi, O. Prostaglandin D2: A neuromodulator. In: “Advances in Prostaglandin, Thromboxane, and Leukotriene Research,” Vol. 12. B. Samuelsson, R. Paoletti, and P. Ramwell, eds. Raven Press, New York, 1983, pp. 333–337.Google Scholar
  17. 17.
    Wolfe, L. S. Eicosanoids: Prostaglandins, thromboxanes, leukotrienes, and other derivatives of carbon-20 unsaturated fatty acids. J. Neurochem. 38: 1–14, 1982.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • M. R. Landauer
    • 1
  • T. L. Walden
    • 2
  • H. D. Davis
    • 1
  • J. A. Dominitz
    • 1
  1. 1.Behavioral Sciences DepartmentArmed Forces Radiobiology Research InstituteBethesdaUSA
  2. 2.Radiation Biochemistry DepartmentArmed Forces Radiobiology Research InstituteBethesdaUSA

Personalised recommendations